Mineralys Therapeutics, Inc. announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension, when used as an add-on therapy to prescribed background treatment. Launch-HTN is the second of two clinical trials under the planned pivotal program to evaluate the safety and efficacyof lorundrostat when added to subjects' existing background hypertension treatment. This trial is designed to model real world treatment of uncontrolled hypertension and resistant hypertension in the primary care setting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.58 USD | -0.87% |
|
-4.26% | +46.28% |
06-14 | Mineralys Therapeutics, Inc. Announces Changes to its Board | CI |
06-13 | Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.28% | 625M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension